Hannah Blau
Overview
Explore the profile of Hannah Blau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
2012
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Antony B, Blau H, Casiraghi E, Loomba J, Callahan T, Laraway B, et al.
EBioMedicine
. 2023 Sep;
96:104777.
PMID: 37672869
Background: The cause and symptoms of long COVID are poorly understood. It is challenging to predict whether a given COVID-19 patient will develop long COVID in the future. Methods: We...
12.
Carmody L, Gargano M, Toro S, Vasilevsky N, Adam M, Blau H, et al.
medRxiv
. 2023 Jul;
PMID: 37503136
Navigating the vast landscape of clinical literature to find optimal treatments and management strategies can be a challenging task, especially for rare diseases. To address this task, we introduce the...
13.
Cohen-Cymberknoh M, Dimand I, Tanny T, Blau H, Mussaffi H, Kadosh D, et al.
J Cyst Fibros
. 2023 Apr;
22(4):772-776.
PMID: 37061352
Background: The hallmarks of Cystic fibrosis (CF), chronic infection and inflammation, require intensive daily treatment to maintain and improve quality of life and outcome. The incidence of Attention Deficit/Hyperactivity Disorder...
14.
Stafler P, Landau E, Blau H
Pediatr Pulmonol
. 2023 Apr;
58(6):1812-1814.
PMID: 37042575
No abstract available.
15.
Casiraghi E, Wong R, Hall M, Coleman B, Notaro M, Evans M, et al.
J Biomed Inform
. 2023 Jan;
139:104295.
PMID: 36716983
Healthcare datasets obtained from Electronic Health Records have proven to be extremely useful for assessing associations between patients' predictors and outcomes of interest. However, these datasets often suffer from missing...
16.
Reese J, Blau H, Casiraghi E, Bergquist T, Loomba J, Callahan T, et al.
EBioMedicine
. 2022 Dec;
87:104413.
PMID: 36563487
Background: Stratification of patients with post-acute sequelae of SARS-CoV-2 infection (PASC, or long COVID) would allow precision clinical management strategies. However, long COVID is incompletely understood and characterised by a...
17.
Chan L, Casiraghi E, Laraway B, Coleman B, Blau H, Zaman A, et al.
Diabetes Res Clin Pract
. 2022 Nov;
194():110157.
PMID: 36400170
Aims: Studies suggest that metformin is associated with reduced COVID-19 severity in individuals with diabetes compared to other antihyperglycemics. We assessed if metformin is associated with reduced incidence of severe...
18.
Coleman B, Casiraghi E, Callahan T, Blau H, Chan L, Laraway B, et al.
medRxiv
. 2022 Nov;
PMID: 36380762
Funding: NCATS U24 TR002306.
19.
Chan L, Casiraghi E, Laraway B, Coleman B, Blau H, Zaman A, et al.
medRxiv
. 2022 Sep;
PMID: 36093353
Background: With the continuing COVID-19 pandemic, identifying medications that improve COVID-19 outcomes is crucial. Studies suggest that use of metformin, an oral antihyperglycemic, is associated with reduced COVID-19 severity in...
20.
Reese J, Blau H, Bergquist T, Loomba J, Callahan T, Laraway B, et al.
medRxiv
. 2022 Jun;
PMID: 35665012
Accurate stratification of patients with post-acute sequelae of SARS-CoV-2 infection (PASC, or long COVID) would allow precision clinical management strategies. However, the natural history of long COVID is incompletely understood...